Ganot Capital

Notal Vision, Inc. is a diagnostic services company focused on enhancing eye disease management by providing home-based ophthalmology diagnostics. The company has developed a range of tools, including ForeseeHome, a monitoring device designed for detecting central and paracentral metamorphopsia in patients with age-related macular degeneration. It utilizes Preferential Hyperacuity Perimetry to identify subtle changes in vision. Additionally, Notal Vision offers the Notal OCT Analyzer, which employs an image analysis algorithm for the automated detection of pathological fluid in exudative retinal diseases, alongside noninvasive optical coherence tomography for imaging. Their AI-driven platform supports at-home testing and facilitates communication between patients and eye care providers. Founded in 2000, Notal Vision operates from offices in Tel Aviv, Israel, and Manassas, Virginia, and aims to improve visual outcomes by extending eye care beyond traditional clinical settings.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

Notal Vision, Inc. is a diagnostic services company focused on enhancing eye disease management by providing home-based ophthalmology diagnostics. The company has developed a range of tools, including ForeseeHome, a monitoring device designed for detecting central and paracentral metamorphopsia in patients with age-related macular degeneration. It utilizes Preferential Hyperacuity Perimetry to identify subtle changes in vision. Additionally, Notal Vision offers the Notal OCT Analyzer, which employs an image analysis algorithm for the automated detection of pathological fluid in exudative retinal diseases, alongside noninvasive optical coherence tomography for imaging. Their AI-driven platform supports at-home testing and facilitates communication between patients and eye care providers. Founded in 2000, Notal Vision operates from offices in Tel Aviv, Israel, and Manassas, Virginia, and aims to improve visual outcomes by extending eye care beyond traditional clinical settings.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

Kyma Medical Technologies is an early-stage medical device company focused on cardiovascular diagnostics. Founded in March 2008, the company is developing a dual modality non-invasive diagnostic system aimed at detecting in-stent restenosis. In addition to its work in cardiovascular diagnostics, Kyma is also creating a remote patient monitoring solution specifically for patients with congestive heart failure. This solution includes a small patch that adheres to the patient's torso, wirelessly transmitting health data to a remote center via a gateway device such as a smartphone.